In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prioritizing Health Care: Reform Gains Early Momentum

Executive Summary

Health care reform advocates think the stars are aligned for a major push toward universal coverage under President-elect Barack Obama. They aren’t about to let the free-falling economy get in the way. This feature is reprinted from The RPM Report, November 2008.

You may also be interested in...



The Value Proposition: Why Pharma Should Embrace Comparative Effectiveness

A greater investment in comparative effectiveness research appears inevitable, whether or not Congress creates a federally funded agency to conduct head-to-head trials. The Vytorin debacle is only the most recent reason why industry is wary. But there are steps pharma can take to prepare for the next big thing in health care policy. Despite Vytorin, Merck is one of the companies leading the way.

Flubbing the FOBs Opportunity: Follow-on Biologics Winners & Losers

An abbreviated pathway for follow-on biologics just missed getting tacked onto the FDA user fee/drug reform legislation. It will be years before proponents get another shot at creating an abbreviated approval pathway for the biotech copycats. So who won and who lost?

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Related Companies

UsernamePublicRestriction

Register

IV003056

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel